VKTX
Viking Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website vikingtherapeutics.com
- Employees(FY) 23
- ISIN US92686J1060
Performance
-5.44%
1W
-28.1%
1M
-27.71%
3M
+168.01%
6M
+179.53%
YTD
+132.34%
1Y
Profile
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Investment Analysis Report: VKTX
Overview
VKTX is a pharmaceutical company operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $3.64 billion. In this report, we will conduct a comprehensive analysis of VKTX's financial statements to evaluate its valuation, fin...
Technical Analysis of VKTX 2024-05-31
Overview:
In analyzing the technical indicators for VKTX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Indicators:
- Moving Averages (MA): The 5-day MA has been consistently below the closing prices, ...
Recent News & Updates
- 2024-06-15 09:31
- 2024-06-15 07:45
- 2024-06-14 05:50
- 2024-06-13 17:45
- 2024-06-13 09:30
- 2024-06-13 05:45
- 2024-06-12 21:30
- 2024-06-11 22:00
3 Stocks Quietly Preparing for a 10X Surge: June Edition(Investorplace)
- 2024-06-11 06:52
Here’s Why Viking Therapeutics (VKTX) Shares Rose in Q1(Insider Monkey)
- 2024-06-10 18:52
Here's Why Viking Therapeutics (VKTX) Shares Rose in Q1(Insidermonkey)
- 2024-06-10 09:45
- 2024-06-09 08:45
- 2024-06-08 07:40
- 2024-06-07 19:40
- 2024-06-07 17:45
- 2024-06-07 05:45
- 2024-06-07 02:52
Viking Therapeutics (VKTX) Shares Rose in Q1(Insider Monkey)
- 2024-06-06 14:52
Viking Therapeutics (VKTX) Shares Rose in Q1(Insidermonkey)
- 2024-06-06 07:45
Is Viking Therapeutics Stock a Buy on the Dip?(Motley Fool)
- 2024-06-06 05:23
The 3 Most Undervalued Pharma Stocks to Buy in June 2024(Investorplace)
- 2024-06-05 10:28
- 2024-06-04 22:28
- 2024-06-04 21:42
Jim Cramer Says You Should Not Buy These 11 Stocks(Insidermonkey)
- 2024-06-04 16:17
Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug(Investor's Business Daily)
- 2024-06-04 13:36
Stocks retreat on weak JOLTS data, HPE, CrowdStrike earnings on tap: Yahoo Finance(Yahoo Finance Video)
- 2024-06-04 08:30
- 2024-06-04 08:00
Viking says biopsy data confirm MASH drug’s benefit(BioPharma Dive)
- 2024-06-04 07:05
- 2024-06-04 06:00
The 3 Most Undervalued Biotech Stocks to Buy in June 2024(InvestorPlace)
- 2024-06-03 19:05
Page 1 of 10
previousnext